As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.
As of Thursday September 3, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence extends the gray zone that began with the April 16, 2026 removal of 12 peptides from Category 2 and continues to leave compounding pharmacies operating under enforcement risk. CDER warning-letter activity to compounding pharmacies remained elevated through Q3 2026 versus prior years. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled; formal FDA rulemaking to translate PCAC recommendations into a proposed rule typically runs 6 to 18 months. The FDA Commissioner nomination of Dr. Heidi Overton continues to await Senate confirmation, with acting Commissioner Kyle Diamantas leading the agency through the interim.
AMC Defense Law's June 2026 'Justice Watch' note read the peptide enforcement signal: compounding pharmacies receiving warning letters and losing licenses, telehealth companies facing criminal indictments, and bulk-substance vendors under federal scrutiny. The FDA has issued more than 50 warning letters to peptide vendors and compounders in 2024-2025, and the agency has signaled an aggressive 503A/503B stance heading into the July 23-24 PCAC meeting that will rule on whether seven peptides return to legal compounding status.